McKesson Corporation extended its pharmaceutical distribution agreement with CVS Health through June 2032. The agreement covers CVS’s mail-order, specialty and retail pharmacies, as well as its distribution centers.
Following the announcement, McKesson shares rose more than 5%. The company reaffirmed its fiscal 2027 adjusted earnings per share guidance of $44.20 to $45.00.
McKesson also reaffirmed its long-term adjusted EPS growth forecast of 13% to 16%.